Seraph-100 hemoperfusion for management of severe COVID-19: Assessment of serum and plasma analytes pre- and post-filtration
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: We report an Intervention/outcome study of 33 severe COVID-19 subjects who received Seraph 100 Microbind Affinity Blood Filter (Seraph 100) hemoperfusion therapy (15 survivors, 18 non-survivors) under emergency authorization from the FDA. Our objective was to determine if Seraph 100 hemoperfusion reduces SARS-CoV-2 RNA titers and/or markers of inflammation and/or epi/endothelial damage. METHODS: Viral RNA and 78 protein analytes related to endothelial/epithelial damage and/or inflammation were quantified in systemic blood samples from 33 severe COVID-19 subjects collected upon intensive care unit (ICU) admission and then immediately before and after blood passed through the heparin-based Seraph 100 filter at two time points on the first day of hemoperfusion. Viral RNA titers were quantified using droplet digital PCR. Protein analytes were quantified using multiplex/multi-analyte panels on MesoScale Discovery and ProteinSimple Ella platforms. RESULTS: A total of 15/33 subjects had detectable viral RNA in baseline samples (shortly after ICU admission). These initial viremia levels were low, and they did not change uniformly post-perfusion. Five of 55 protein analytes that were upregulated 1.4-120X at ICU admission relative to healthy controls showed significant decreases across the filter during the indicated time points on the first day of hemoperfusion: IP-10/CXCL10, fms-like tyrosine kinase 1, MIG/CXCL9, hepatocyte growth factor (HGF), and receptor for advanced glycosylation end products (RAGE). Paired t tests identified 25 additional analytes that showed significant decreases (p < 0.05) only without Bonferroni correction. CONCLUSION: Initial freely circulating SARS-CoV-2 RNA levels of ICU-admitted subjects were low or undetectable. The Seraph 100 filter did not significantly reduce viral RNA titers in their plasma. However, multiple circulating proteins with roles in inflammation, endothelial/epithelial damage, and/or angiogenesis decreased significantly across the filter. Larger prospective trials will be required to determine if such transient reductions translate into improved patient outcomes. However, this study did not demonstrate a direct reduction of free SARS-CoV-2 viral RNA by the Seraph 100.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Seraph-100 hemoperfusion for management of severe COVID-19: Assessment of serum and plasma analytes pre- and post-filtration
- Date Crossref
- 11/12/2024
- Éditeur
- S. Karger AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Henry M. Jackson Foundation pays non établi dans la noticeOrganisation à but non lucratif
-
Uniformed Services University of the Health Sciences Department of Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Walter Reed National Military Medical Center pays non établi dans la noticeÉtablissement de santé
-
Outcomes Research Consortium pays non établi dans la noticeOrganisation à but non lucratif
-
Naval Medical Research Command pays non établi dans la noticeStructure de recherche
-
Methodist Hospital pays non établi dans la noticeÉtablissement de santé
-
Methodist Children’s Hospital pays non établi dans la noticeÉtablissement de santé
-
Southeast Georgia Health System pays non établi dans la noticeÉtablissement de santé
-
Eisenhower Medical Center pays non établi dans la noticeÉtablissement de santé
-
VA Greater Los Angeles Healthcare System pays non établi dans la noticeÉtablissement de santé
-
The University of Texas Southwestern Medical Center pays non établi dans la noticeÉtablissement de santé
-
AdventHealth Orlando pays non établi dans la noticeÉtablissement de santé
Henry M. Jackson Foundation, Department of Surgery — Uniformed Services University of the Health Sciences et Walter Reed National Military Medical Center, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.